ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

6 results sorted by trial registration date.
Clear all

  • Testing a new sleep mat, the Sonomat for use to diagnose sleep breathing problems in children with Neurodisability

    The Sonomat is a non-invasive sleep mat which has recently been validated in children. The primary aim of this study is to evaluate the potential clinical application of the Sonomat, in children with Neurodisability. Participants will undergo sonomat monitoring at the same time as having their in lab sleep study (polysonomgraphy - PSG) and then use the mat at home for three nights. We hypothesise that the sonomat will be comparable to an in lan sleep study for the diagnosis of sleep disordered breathing in children with neurodisability.

    Registration number:
    ACTRN12622001544763
    Broad health category:
    • Respiratory
    • Neurological
    Specific health category:
    • Sleep apnoea
    • Other neurological disorders
    Trial focus:
    • Diagnosis
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • QLD
    • VIC
    Gender:
    • All

  • Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS

    The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).

    Registration number:
    NCT06617429
    Broad health category:
    • Angelman Syndrome
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Long-term Extension of GTX-102 in Angelman Syndrome

    The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

    Registration number:
    NCT06415344
    Broad health category:
    • Angelman Syndrome
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • QLD
    • VIC
    • Not specified
    Gender:
    • All

  • A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

    This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.

    Registration number:
    NCT05630066
    Broad health category:
    • Angelman Syndrome
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • QLD
    • SA
    • Not specified
    Gender:
    • All

  • The Global Angelman Syndrome Registry

    The Global Angelman Syndrome Registry is an online patient organisation driven registry to collect information about the natural history of children and adults with Angelman Syndrome. The registry will facilitate 1) recruitment for clinical trials into therapies and interventions to benefit participants with Angelman Syndrome and their families, and 2) advancement of research and best standards of care for Angelman Syndrome. The registry is currently available in English, Spanish, Traditional Chinese, Italian, Polish, Hindi, and Brazilian Portuguese.

    Registration number:
    NCT05293184
    Broad health category:
    • Angelman Syndrome
    Specific health category:
    • Not specified
    Trial focus:
    • Not specified
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • QLD
    • Not specified
    Gender:
    • All

  • Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

    ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery). The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms. Participants from the ZYN2-CL-016 and ZYN2-CL-033 studies who meet the inclusion criteria and none of the exclusion criteria for study ZYN2-CL-017 are eligible. Parents/caregivers will apply the study gel twice daily for the 52-week treatment period.

    Registration number:
    NCT03802799
    Broad health category:
    • Fragile X Syndrome
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • QLD
    • VIC
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials